Literature DB >> 11408331

End-plate gamma- and epsilon-subunit mRNA levels in AChR deficiency syndrome due to epsilon-subunit null mutations.

R Croxen1, C Young, C Slater, S Haslam, M Brydson, A Vincent, D Beeson.   

Abstract

Acetylcholine receptor (AChR) deficiency is the most common of the congenital myasthenic syndromes (CMS). Typically, the number of AChRs, measured by alpha-bungarotoxin binding, is reduced to 10-30% of normal levels, the miniature end-plate potentials are correspondingly reduced, and there are morphological changes at the motor end-plates. The majority of these syndromes are due to either missense or frameshift mutations within the gene encoding the adult-specific epsilon-subunit. These are often null mutations, but some mutant epsilon-subunits can be incorporated, at low levels, into functional AChRs in transfected cell lines. It is not clear, therefore, whether upregulation of the mutant epsilon-subunit mRNA could generate sufficient AChR to support neuromuscular transmission, albeit at a reduced level. Conversely, it might be that the mutant epsilon-subunit transcripts are subject to mRNA surveillance and 'nonsense-mediated' loss, leading to reduced epsilon-subunit mRNA expression. In either case, it is thought that neuromuscular transmission may be provided partly or entirely by incorporation of the foetal-specific gamma-subunit into end-plate AChR. gamma-Subunit mRNA is expressed at low levels in normal human muscle, but might be upregulated in CMS. The study of mRNA levels for AChR subunits should improve our understanding of genotype-phenotype relationships in CMS. Here we have defined homozygous epsilon-subunit mutations in four unrelated families with AChR deficiency and studied the steady-state levels of mRNA for AChR subunits at the motor end-plates by in situ hybridization. Although we demonstrated that each mutation would lead to almost complete absence of surface adult AChR expression, we detected similar robust expression of alpha- and epsilon-subunit mRNAs at end-plates of patient and control muscles, suggesting that mRNA transcripts for the epsilon-subunit are neither upregulated nor degraded preferentially. Interestingly, we were unable to detect any increase in gamma-subunit mRNA expression at CMS end-plates. Transgenic mice lacking the epsilon-subunit die 2-3 months after birth, suggesting that alpha(2)betadelta(2) pentamers cannot sustain neuromuscular transmission. Therefore, we tentatively conclude that the persistent low level expression of the gamma-subunit, which is present in normal human muscles as well as in AChR deficiency syndromes, is sufficient to enable patients with epsilon-subunit null alleles to survive.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11408331     DOI: 10.1093/brain/124.7.1362

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  12 in total

1.  hnRNP H enhances skipping of a nonfunctional exon P3A in CHRNA1 and a mutation disrupting its binding causes congenital myasthenic syndrome.

Authors:  Akio Masuda; Xin-Ming Shen; Mikako Ito; Tohru Matsuura; Andrew G Engel; Kinji Ohno
Journal:  Hum Mol Genet       Date:  2008-09-20       Impact factor: 6.150

2.  Identification of DPAGT1 as a new gene in which mutations cause a congenital myasthenic syndrome.

Authors:  Katsiaryna Belaya; Sarah Finlayson; Judith Cossins; Wei Wei Liu; Susan Maxwell; Jacqueline Palace; David Beeson
Journal:  Ann N Y Acad Sci       Date:  2012-12       Impact factor: 5.691

3.  Neuromuscular junctions (NMJs): ultrastructural analysis and nicotinic acetylcholine receptor (nAChR) subunit mRNA expression in offspring subjected to protein restriction throughout pregnancy.

Authors:  Paula Aiello Tomé de Souza Castro; Ludimila Canuto Faccioni; Patrícia Aline Boer; Robson Francisco Carvalho; Selma Maria Michelin Matheus; Maeli Dal-Pai-Silva
Journal:  Int J Exp Pathol       Date:  2017-05-25       Impact factor: 1.925

Review 4.  Congenital myasthenic syndromes: genetic defects of the neuromuscular junction.

Authors:  Kinji Ohno; Andrew G Engel
Journal:  Curr Neurol Neurosci Rep       Date:  2002-01       Impact factor: 5.081

5.  Mutations in DPAGT1 cause a limb-girdle congenital myasthenic syndrome with tubular aggregates.

Authors:  Katsiaryna Belaya; Sarah Finlayson; Clarke R Slater; Judith Cossins; Wei Wei Liu; Susan Maxwell; Simon J McGowan; Siarhei Maslau; Stephen R F Twigg; Timothy J Walls; Samuel I Pascual Pascual; Jacqueline Palace; David Beeson
Journal:  Am J Hum Genet       Date:  2012-06-27       Impact factor: 11.025

6.  Rapsyn facilitates recovery from desensitization in fetal and adult acetylcholine receptors expressed in a muscle cell line.

Authors:  Hakan Cetin; Wei Liu; Jonathan Cheung; Judith Cossins; An Vanhaesebrouck; Susan Maxwell; Angela Vincent; David Beeson; Richard Webster
Journal:  J Physiol       Date:  2019-06-17       Impact factor: 5.182

7.  AChR deficiency due to epsilon-subunit mutations: two common mutations in the Netherlands.

Authors:  Catharina G Faber; Peter C Molenaar; Johannes S H Vles; Domenic M Bonifati; Jan J G M Verschuuren; Pieter A van Doorn; Jan B M Kuks; John H J Wokke; David Beeson; Marc De Baets
Journal:  J Neurol       Date:  2009-06-21       Impact factor: 4.849

8.  Contrasting properties of α7-selective orthosteric and allosteric agonists examined on native nicotinic acetylcholine receptors.

Authors:  JasKiran K Gill; Anna Chatzidaki; Daniel Ursu; Emanuele Sher; Neil S Millar
Journal:  PLoS One       Date:  2013-01-29       Impact factor: 3.240

Review 9.  Animal Models of the Neuromuscular Junction, Vitally Informative for Understanding Function and the Molecular Mechanisms of Congenital Myasthenic Syndromes.

Authors:  Richard G Webster
Journal:  Int J Mol Sci       Date:  2018-04-29       Impact factor: 5.923

10.  The MX-Helix of Muscle nAChR Subunits Regulates Receptor Assembly and Surface Trafficking.

Authors:  Jolene Chang Rudell; Lucia Soares Borges; Vladimir Yarov-Yarovoy; Michael Ferns
Journal:  Front Mol Neurosci       Date:  2020-03-24       Impact factor: 5.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.